Mutation in the PCSK9 gene in Omani Arab subjects with autosomal dominant hypercholesterolemia and its efect on PCSK9 protein structure

Oman Medical Journal

Volumn 28, Issue 1, 2013, Pages 48-52

  Al Waili, Khalid ^a   Al Zidi, Ward Al Muna ^a   Al Abri, Abdul Rahim ^a   Al Rasadi, Khalid ^a   Al Sabti, Hilal Ali ^c   Shah, Karna ^b   Al Futaisi, Abdullah ^d   Al Zakwani, Ibrahim ^a   Banerjee, Yajnavalka ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^d OMAN MEDICAL SPECIALTY BOARD   (Oman)

Author keywords

Autosomal dominant hypercholesterolemia; Mutation; PCSK9 protien

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; SUBTILISIN; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; CASE REPORT; COMPUTER MODEL; DNA SEQUENCE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873302752     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2013.11     Document Type: Article

References (20)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004 Sep;160(5):407-420.
2. Abifadel M, Varret M, Rabès J P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 Jun;34(2):154-156.
3. Marques-Pinheiro A, Marduel M, Rabès JP, Devillers M, Villéger L, Allard D, et al; French Research Network on ADH. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1. Eur J Hum Genet 2010 Nov;18(11):1236-1242.
4. Cenarro A, García-Otín AL, Tejedor MT, Solanas M, Jarauta E, Junquera C, et al. A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clin Genet 2011 May;79(5):475-481.
5. Banerjee Y, Shah K, Al-Rasadi K. Efect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012 Jun;366(25):2425-2426
6. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. Te secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal diferentiation. Proc Natl Acad Sci U S A 2003 Feb;100(3):928-933.
7. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and efects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004 Nov;279(47):48865-48875.
8. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005 Nov;26(5):497.
9. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005 Feb;37(2):161-165.
10. Al-Hinai AT, Al-Abri A, Al-Dhuhli H, Al-Waili K, Al-Sabti H, Al-Yaarubi S, et al. First Case Report of Familial Hypercholesterolemia in an Omani Family due to Novel Mutation in the Low-Density Lipoprotein Receptor Gene. Angiology 2012 Nov.
11. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982 May;157(1):105-132.
12. Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T. Te SWISS-MODEL Repository and associated resources. Nucleic Acids Res 2009 Jan;37(Database issue):D387-D392.
13. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009 Apr;284(16):10561-10570.
14. Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain confgurations. J Mol Biol 1963 Jul;7:95-99.
15. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006 Mar;78(3):410-422.
16. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008 Jan;196(1):29-36.
17. Shioji K, Mannami T, Kokubo Y, Inamoto N, Takagi S, Goto Y, et al. Genetic variants in PCSK9 afect the cholesterol level in Japanese. J Hum Genet 2004;49(2):109-114.
18. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and efects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004 Nov;279(47):48865-48875.
19. Ding K, McDonough SJ, Kullo IJ. Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS One 2007;2(10):e1098.
20. Hussin J, Sinnett D, Casals F, Idaghdour Y, Bruat V, Saillour V, et al. Rare allelic forms of PRDM9 associated with childhood leukemogenesis. Genome Res 2012 Dec.